TrialAdvances in therapy2019

Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.

Michael J Palte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.